Covid-19 and drug therapy, what we learned

Alessio Provenzani, Piera Polidori

Research output: Contribution to journalReview articlepeer-review

Abstract

COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.

Original languageEnglish
Pages (from-to)833-836
Number of pages4
JournalInternational Journal of Clinical Pharmacy
Volume42
Issue number3
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Antiviral Agents/pharmacology
  • Betacoronavirus/drug effects
  • COVID-19
  • China
  • Coronavirus Infections/drug therapy
  • Humans
  • Pandemics
  • Pneumonia, Viral/drug therapy
  • SARS-CoV-2

Fingerprint Dive into the research topics of 'Covid-19 and drug therapy, what we learned'. Together they form a unique fingerprint.

Cite this